Satya Das, MD, MSCI, on Research Presented at the 2021 ASCO Gastrointestinal Cancer Symposium
The expert in hematology/oncology discussed what research he is most looking forward to seeing the results of at the meeting.
Satya Das, MD, MSCI, on the Impact of PRRT in Patients With Well-Differentiated NETs
The expert in hematology/oncology discussed the implications of a study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
Satya Das, MD, MSCI, on the Use of PRRT in Patients With Well-Differentiated NETs
The expert in hematology/oncology discussed the results of a study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
Satya Das, MD, MSCI, on the Design of a Study of PRRT in Patients With Well-Differentiated NETs
The expert in hematology/oncology spoke about the study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.